Congestive Heart Failure Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function Given a Standard Dose of Loop Diuretic
Verified date | February 2021 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to investigate continuous 8-hour introductions of BMS-986231 in participants with heart failure and weakened heart function given a standard dose of diuretic.
Status | Completed |
Enrollment | 23 |
Est. completion date | January 9, 2020 |
Est. primary completion date | December 11, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Left ventricular ejection fraction <45%, as assessed by echocardiography, a multigated acquisition (MUGA) scan or magnetic resonance imaging (MRI) scan within 18 months - On stable chronic guideline-directed therapy for HF including chronic loop diuretics, ACEi, ARBs, MRAs, ARNI or / and ß-blockers as tolerated, with no changes of these medications in the past 2 weeks - At least an oral dose of 40 mg of furosemide/day or equivalent (20 mg torsemide, 1 mg bumetamide) Exclusion Criteria: - SBP < 115 mm Hg or > 180 mm Hg at screening or pre-randomization - Heart rate < 50 beats per minute (bpm) or > 120 bpm at screening or pre-randomization - Primary HF etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic or uncorrected severe valvular disease Other protocol defined inclusion/exclusion criteria could apply |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Glasgow Clinical Research Facility | Glasgow | |
United Kingdom | Richmond Pharmacology | London |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 4-hour Urinary Output Following Intravenous Administration of 40 mg Furosemide to HFrEF Participants Receiving BMS-986231 Infusion Compared to Placebo | The total volume of urinary output 4 hours after 40 mg furosemide bolus given to participants with HFrEF while on BMS-986231 compared to placebo: absolute difference in total volume and % change from placebo.
Sequence 1: Placebo in period 1, drug in period 2 Sequence 2: Drug in period 1, placebo in period 2 |
4 hours | |
Secondary | FeNa in Participants With HFrEF While on BMS-986231 Compared to Placebo | Secondary efficacy analyses was performed using the randomized population. The FeNa, FeK, furosemide urinary and plasma concentration and the ratio of urinary sodium to urinary furosemide was calculated at each time point over 4-hour urine/plasma collection after a bolus injection of 40 mg furosemide while receiving BMS-986231 or placebo.
Fractional Excretion Na = ((Urine Sodium * Plasma Creatinine) / (Plasma Sodium * Urine Creatinine)) * 100 |
Day 1, predose; 0-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours | |
Secondary | FeK in Participants With HFrEF While on BMS-986231 Compared to Placebo | Secondary efficacy analyses was performed using the randomized population. The FeNa, FeK, furosemide urinary and plasma concentration and the ratio of urinary sodium to urinary furosemide was calculated at each time point over 4-hour urine/plasma collection after a bolus injection of 40 mg furosemide while receiving BMS-986231 or placebo.
Fractional Excretion K = ((Urine Potassium * Plasma Creatinine) / (Plasma Potassium * Urine Creatinine)) * 100 |
Day 1, predose; 0-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours | |
Secondary | Furosemide Urinary Concentrations | Summary of urine recovery by interval, measured by amount excreted. | Day 1, predose, 0-2 hours, 2-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours, 8-10 hours | |
Secondary | Furosemide Plasma Concentrations | Summary of plasma concentrations by interval. | Day 1: 4, 5, 6, 8, 10 hours | |
Secondary | Ratio Urinary Sodium (Na) to Urinary Furosemide at 8 Hours Post-start Infusion | Summary of urinary concentrations 0-4 hours after furosemide
Ratio = Cumulative Sodium Excretion / Cumulative Furosemide in Urine |
0-4 hours after furosemide | |
Secondary | Number of Participants With Clinically Relevant Hypotension | Clinically relevant hypotension is defined as systolic blood pressure (SBP) < 90 mmHg or symptomatic hypotension during infusion | up to 8 hours | |
Secondary | Number of Participants With an Adverse Event (AE) | Clinically relevant hypotension is defined as systolic blood pressure (SBP) < 90 mmHg or symptomatic hypotension during infusion | up to 8 days | |
Secondary | Number of Participants With an Abnormal Clinical Laboratory Value | Number of participants who experienced an in-study abnormal clinical laboratory event under the category of Hematology, Chemistry or Urinalysis. | from first dose to 30 days post-last dose (ca. 5-8 weeks) | |
Secondary | Change From Baseline in Vital Signs - Blood Pressure | The change in baseline for vital signs was reported for each arm. | Day 1, 8 hours post-dose (end of infusion) | |
Secondary | Change From Baseline in Vital Signs - Heart Rate | The change in baseline for vital signs was reported for each arm. | Day 1, 8 hours post-dose (end of infusion) | |
Secondary | Change From Baseline in Vital Signs - Oxygen Saturation | The change in baseline for vital signs was reported for each arm. | Day 1, 8 hours post-dose (end of infusion) | |
Secondary | Change From Baseline in Electrocardiograms (ECGs) - Mean Heart Rate | The change in baseline for ECGs was reported for each arm. | Day 1, 8 hours post-dose (end of infusion) | |
Secondary | Change From Baseline in Electrocardiograms (ECGs) - PR, QRS Duration, QT, QTcF Intervals | The change in baseline for ECGs was reported for each arm. | Day 1, 8 hours post-dose (end of infusion) | |
Secondary | Telemetry | Telemetry data not collected. | Day 1, 8 hours post-dose | |
Secondary | Change From Baseline in Physical Examination - Body Weight | The change in baseline for physical examinations was reported for each arm. | Day 1, 8 hours post-dose (end of infusion) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT04037436 -
Functional Exercise and Nutrition Education Program for Older Adults
|
N/A | |
Recruiting |
NCT04703842 -
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
|
Phase 1/Phase 2 | |
Terminated |
NCT05594940 -
Heart Failure Monitoring With a Portable Ultrasound Device With Artificial Intelligence Assisted Tools: A Multi-Phase Observational Feasibility Study
|
||
Recruiting |
NCT04982081 -
Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
|
Phase 1 | |
Completed |
NCT04394754 -
Evaluating Efficacy of Digital Health Technology in the Treatment of Congestive Heart Failure
|
N/A | |
Active, not recruiting |
NCT01385176 -
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
|
N/A | |
Not yet recruiting |
NCT05516290 -
Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure
|
||
Terminated |
NCT02788656 -
Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)
|
Phase 4 | |
Completed |
NCT02885636 -
Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial
|
Phase 3 | |
Terminated |
NCT02205411 -
Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation
|
N/A | |
Completed |
NCT02252757 -
Assess Measurements of Wireless Cardiac Output Device
|
N/A | |
Completed |
NCT01362855 -
Advance Care Planning Evaluation in Hospitalized Elderly Patients
|
||
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Withdrawn |
NCT00346177 -
Stem Cell Study for Patients With Heart Failure
|
Phase 2 | |
Active, not recruiting |
NCT01058837 -
SCD-HeFT 10 Year Follow-up
|
N/A | |
Completed |
NCT00957541 -
Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device
|
Phase 2 |